Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the therapy.
Stocktwits
More News
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
Replimune said the U.S. Food and Drug Administration granted accelerated approval for TUDRIQEV, previously known as RP1, in combination with nivolumab.
Stocktwits
NVAX Stock Holds Steady As Novavax Lifts Revenue Outlook On Licensing Pivot — Retail Eyes Buyout, More Partnership Deals
Novavax raised its full-year 2026 adjusted total revenue outlook to $235–$275 million from $230–$270 million.
Stocktwits
IOVA Stock Heads For Best Day In Over 6 Years – Buyout Buzz Builds After Blowout Q2
The biotech company reported record second-quarter revenue fueled by strong sales of its cancer therapy Amtagvi.
The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.
Stocktwits
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales
ImmunityBio’s record quarterly revenue of $51.2 million beat Wall Street’s estimates of $49.7 million, driven by the increased sales of Anktiva.
Stocktwits
Replimune’s Melanoma FDA Decision Pending: This Analyst Sees 40% Upside, ‘High Conviction’ For Approval
The brokerage expects Replimune’s RP1 drug to see strong demand if approved, citing its relative ease of access and favorable safety profile.
Stocktwits
IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback
On July 29, UAE regulators approved ImmunityBio’s main cancer drug ANKTIVA for two indications, sparking a rally the next day.
Stocktwits
NVAX Stock Rises Ahead Of Q2 Earnings As Focus Shifts To Licensing Deals
Novavax is scheduled to release its second-quarter 2026 financial results before the U.S. market opens on Thursday.
Stocktwits
Eli Lilly’s Olomorasib Secures Second FDA Breakthrough Designation For Cancer Therapy – Retail Expects LLY Stock To Hit Record High Soon
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to Lilly’s drug for advanced pancreatic cancer.
